Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C62H86N12O16 |
Molecular Weight | 1255.417 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C3=C4N=C5C(OC4=C(C)C=C3)=C(C)C(=O)C(N)=C5C(=O)N[C@H]6[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@H](NC6=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C
InChI
InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N
InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954
Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 |
156.25 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
25.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931 |
1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
142.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.67 μg × min/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931 |
1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931 |
1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Other AEs: Pancytopenia, Mucositis... Other AEs: Pancytopenia (1 patient) Sources: Mucositis (severe, 1 patient) Pancreatitis (1 patient) Hyponatremia (1 patient) Hypocalcemia (1 patient) Respiratory distress (1 patient) Melena (1 patient) |
0.15 ug/kg multiple, intravenous (total) Highest studied dose Dose: 0.15 ug/kg Route: intravenous Route: multiple Dose: 0.15 ug/kg Sources: |
unhealthy, 40-77 years n = 2 Health Status: unhealthy Condition: malignant melanoma Age Group: 40-77 years Sex: F Population Size: 2 Sources: |
|
1.5 mg/m2 single, intravenous Highest studied dose Dose: 1.5 mg/m2 Route: intravenous Route: single Dose: 1.5 mg/m2 Sources: |
unknown, children n = 1 Health Status: unknown Age Group: children Population Size: 1 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypocalcemia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Hyponatremia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Melena | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Pancreatitis | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Pancytopenia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Respiratory distress | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Mucositis | severe, 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. | 1999 Apr |
|
Nitric oxide ameliorates actinomycin D/endotoxin-induced apoptotic liver failure in mice. | 1999 Aug |
|
Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. | 1999 Dec 10 |
|
Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. | 1999 Jun 15 |
|
Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells. | 1999 Oct 29 |
|
Polysaccharide Krestin enhances manganese superoxide dismutase activity and mRNA expression in mouse peritoneal macrophages. | 2000 |
|
Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin--preliminary report about hepatoprotective effect of amifostine. | 2000 May-Jun |
|
Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. | 2000 Oct |
|
Modification of biophysical properties of lung epithelial Na(+) channels by dexamethasone. | 2000 Sep |
|
Amphetamine induces differential changes in the gene expression of metabotropic glutamate receptor 5 in cultured cortical and hippocampal neurons. | 2001 Aug |
|
Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. | 2001 Dec |
|
Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. | 2001 Dec 21 |
|
The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. | 2001 Feb |
|
Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells. | 2001 Feb 1 |
|
Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression. | 2001 May |
|
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. | 2001 Sep 11 |
|
Constitutive and inducible expression of Cyp1a1 and Cyp1b1 in vascular smooth muscle cells: role of the Ahr bHLH/PAS transcription factor. | 2001 Sep 28 |
|
Effect of actinomycin D on simian rotavirus (SA11) replication in cell culture. | 2002 Apr |
|
Pathways of induction of peroxiredoxin I expression in osteoblasts: roles of p38 mitogen-activated protein kinase and protein kinase C. | 2002 Apr 5 |
|
Interleukin 1beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells. | 2002 Dec |
|
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. | 2002 Dec 1 |
|
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. | 2002 Jan |
|
Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. | 2002 Jan 1 |
|
Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis. | 2002 May 17 |
|
Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. | 2003 Dec 20 |
|
An efficient, nonenzymatic method for isolation and culture of murine aortic endothelial cells and their response to inflammatory stimuli. | 2003 Jan-Feb |
|
Regulation of rat intestinal GLUT2 mRNA abundance by luminal and systemic factors. | 2003 Jun 10 |
|
Differential expression of c-fos and c-myc protooncogenes by estrogens, xenobiotics and other growth-stimulatory agents in primary rat hepatocytes. | 2003 Mar |
|
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. | 2003 Mar 15 |
|
Interplay between transcriptional and post-transcriptional regulation of Cyp2a5 expression. | 2003 May 15 |
|
Thyroid hormone activates fibroblast growth factor receptor-1 in bone. | 2003 Sep |
|
Dactinomycin-induced veno-occlusive disease in rats. The hepatoprotective action of amifostine. Evaluation in a light and electron microscope. | 2004 Feb |
|
Quercetin enhances melanogenesis by increasing the activity and synthesis of tyrosinase in human melanoma cells and in normal human melanocytes. | 2004 Feb |
|
Cytoprotective effects of heme oxygenase-1 induction by 3-O-caffeoyl-1-methylquinic acid. | 2004 Jan 1 |
|
Mechanism of heme oxygenase-1 gene induction by quercetin in rat aortic smooth muscle cells. | 2004 Jun |
|
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. | 2004 Nov |
|
2-Substituted benzoxazinone analogues as anti-human coronavirus (anti-HCoV) and ICAM-1 expression inhibition agents. | 2004 Sep 20 |
|
Coordinated secretion of alkaline phosphatase into serum and intestine in fat-fed rats. | 2004 Sep-Oct |
|
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1. | 2005 Apr |
|
Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. | 2005 Feb 25 |
|
Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. | 2005 Jan 1 |
|
Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. | 2005 Jan 14 |
|
Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. | 2005 Mar |
|
Mitochondrial redox state regulates transcription of the nuclear-encoded mitochondrial protein manganese superoxide dismutase: a proposed adaptive response to mitochondrial redox imbalance. | 2005 Mar 1 |
Patents
Sample Use Guides
Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.
Route of Administration:
Intravenous
Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C204
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
NDF-RT |
N0000000233
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
LIVERTOX |
NBK548778
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
IARC | Actinomycin D | ||
|
NDF-RT |
N0000000150
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
NDF-RT |
N0000180850
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
WHO-ATC |
L01DA01
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
WHO-VATC |
QL01DA01
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1162400
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
3220
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
457193
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
DB00970
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
m4067
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
Dactinomycin
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
SUB129914
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
50-76-0
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
1CC1JFE158
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
C412
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
200-063-6
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
DTXSID9020031
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
1CC1JFE158
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
DACTINOMYCIN
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | Description: An orange-red to red, crystalline powder.Solubility: Soluble in water at 10 ?C and slightly soluble in water at 37 ?C; freely soluble in ethanol (~750 g/l) TS and methanol R;very slightly soluble in ether R.Category: Cytotoxic drug.Storage: Dactinomycin should be kept in a tightly closed container, protected from light, and stored at a temperature notexceeding 40 ?C.Additional information: Dactinomycin is hygroscopic and is affected by light and heat.CAUTION: Dactinomycin must be handled with care, avoiding contact with the skin and inhalation of airborne particles. | ||
|
SUB13528MIG
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
27666
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
D003609
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL1554
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
100000085032
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
1155
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
3100
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | RxNorm | ||
|
Dactinomycin
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
774
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
3053
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY